{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:22:48Z","timestamp":1794669768651,"version":"4.9.1"},"reference-count":110,"publisher":"American Chemical Society (ACS)","issue":"4","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2025,4,7]]},"DOI":"10.1021\/acs.molpharmaceut.4c01309","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T10:38:06Z","timestamp":1741603086000},"page":"1775-1789","source":"Crossref","is-referenced-by-count":4,"title":["Biopharmaceutics Aspects of Sugar Alcohols: Implementation of Patient-Centricity in Pharmaceutical Development and Clinical Use"],"prefix":"10.1021","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-2089","authenticated-orcid":true,"given":"Kazuki","family":"Matsui","sequence":"first","affiliation":[{"name":"Biopharmaceutics Group, Pharmaceutical R&D, Ono Pharmaceutical Co., Ltd., 3-1-1, Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24299"},{"key":"ref2\/cit2","unstructured":"ICH.  International Conference on Harmonisation of Technical\nRequirements for Registration of Pharmaceuticals for Human Use (ICH),\nQ9(R1): Quality risk management. 2023."},{"key":"ref3\/cit3","unstructured":"FDA.  SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up\nand Post-Approval Changes: Chemistry, Manufacturing and Controls,\nIn Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. 1995."},{"key":"ref4\/cit4","unstructured":"ICH.  International Conference on Harmonisation of Technical\nRequirements for Registration of Pharmaceuticals for Human Use (ICH),\nM13: Bioequivalence for immediate-release solid oral dosage forms. 2024."},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1943"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2019.05.020"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1007\/s00217-015-2437-7"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101362"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.3109\/10837450.2013.775154"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119890"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.4103\/0250-474X.110587"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.3390\/ph15091091"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13030387"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010119"},{"key":"ref15\/cit15","unstructured":"EMA.  Annex to the European Commission guideline\non \u2018Excipients\nin the labelling and package leaflet of medicinal products for human\nuse\u2019 (SANTE-2017\u201311668) - Revision 4. 2024. https:\/\/www.ema.europa.eu\/en\/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use (accessed 2024 Sep-17)."},{"key":"ref16\/cit16","unstructured":"FDA.  FDA Inactive Ingredient Database. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm (accessed 2024 Oct-1st)."},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2012.10.007"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-201x.1999.00510.x"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.055"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1029"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14754"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.3.376"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00561-y"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143690"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(86)90573-1"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04309.x"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016220428705"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20763"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.10.001"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24433"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.04.030"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016251624220"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12449"},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.386"},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016256619309"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04466.x"},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2006.00757.x"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-3100-8"},{"key":"ref39\/cit39","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010927026837"},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000008046.64409.bd"},{"key":"ref41\/cit41","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600841205"},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91500-4"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018841402133"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011020025338"},{"key":"ref45\/cit45","doi-asserted-by":"publisher","DOI":"10.1021\/jm9810102"},{"key":"ref46\/cit46","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1997.tb06084.x"},{"key":"ref47\/cit47","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(91)90056-T"},{"key":"ref48\/cit48","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2152"},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012121632357"},{"key":"ref50\/cit50","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9120-4"},{"key":"ref51\/cit51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2006.10.011"},{"key":"ref52\/cit52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.08.001"},{"key":"ref53\/cit53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.808456"},{"key":"ref54\/cit54","doi-asserted-by":"publisher","DOI":"10.1177\/096032719000900310"},{"key":"ref55\/cit55","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.943"},{"key":"ref56\/cit56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04105.x"},{"key":"ref57\/cit57","unstructured":"USA,\nG.  Highlights of Prescribing Information:\nTamiflu\u00ae (oseltamivir\nphosphate) for oral suspension. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021246s038lbl.pdf (accessed 2024 Sep-17th)."},{"issue":"8","key":"ref58\/cit58","first-page":"539","volume":"47","author":"Lennon S.","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref59\/cit59","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2024.100734"},{"key":"ref60\/cit60","doi-asserted-by":"publisher","DOI":"10.1177\/0300060513503762"},{"key":"ref61\/cit61","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24643"},{"key":"ref62\/cit62","doi-asserted-by":"publisher","DOI":"10.5414\/CPP45293"},{"key":"ref63\/cit63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.09.004"},{"key":"ref64\/cit64","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.028"},{"key":"ref65\/cit65","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181e2189d"},{"key":"ref66\/cit66","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1931"},{"key":"ref67\/cit67","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.225"},{"key":"ref68\/cit68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1313942"},{"key":"ref69\/cit69","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0311-9"},{"key":"ref70\/cit70","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03071.x"},{"key":"ref71\/cit71","unstructured":"Janssen.  Highlights of Prescribing Information: Risperdal\u00ae\n(risperidone) tablets, for oral use. FDA, 2007. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020272s085,020588s072,021444s058lbl.pdf."},{"key":"ref72\/cit72","unstructured":"ICH.  International Conference on Harmonisation\nof Technical\nRequirements for Registration of Pharmaceuticals for Human Use (ICH),\nM9: Biopharmaceutics classification system based biowaiver. 2019."},{"key":"ref73\/cit73","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.05.013"},{"key":"ref74\/cit74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101728"},{"key":"ref75\/cit75","unstructured":"EMA.  Reflection paper on formulations of choice\nfor the pediatric\npopulation. 2006."},{"key":"ref76\/cit76","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-012-1872-8"},{"key":"ref77\/cit77","doi-asserted-by":"publisher","DOI":"10.1177\/2168479018791133"},{"key":"ref78\/cit78","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12040316"},{"key":"ref79\/cit79","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001660"},{"key":"ref80\/cit80","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1695"},{"key":"ref81\/cit81","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001116"},{"key":"ref82\/cit82","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21744"},{"key":"ref83\/cit83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.04.020"},{"key":"ref84\/cit84","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1147"},{"key":"ref85\/cit85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.12.047"},{"key":"ref86\/cit86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105934"},{"issue":"6","key":"ref87\/cit87","first-page":"480","volume":"22","author":"Cutaia K.","year":"2018","journal-title":"Int. J. Pharm. Compd."},{"key":"ref88\/cit88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.107001"},{"key":"ref89\/cit89","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00919"},{"key":"ref90\/cit90","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b23-00490"},{"key":"ref91\/cit91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04324.x"},{"key":"ref92\/cit92","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.084483"},{"key":"ref93\/cit93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2004.11.005"},{"key":"ref94\/cit94","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00548-8"},{"key":"ref95\/cit95","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00794-6"},{"key":"ref96\/cit96","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12279"},{"key":"ref97\/cit97","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.11.008"},{"key":"ref98\/cit98","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00809-2"},{"key":"ref99\/cit99","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44742-y"},{"key":"ref100\/cit100","doi-asserted-by":"publisher","DOI":"10.1021\/mp500210c"},{"key":"ref101\/cit101","unstructured":"Mylan.  Highlights of Prescribing Information: Lamivudine Tablets. FDA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/pepfar\/078545PI.pdf. (accessed 2024 Sep-19)."},{"key":"ref102\/cit102","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11110567"},{"key":"ref103\/cit103","doi-asserted-by":"publisher","DOI":"10.1021\/mp0600182"},{"key":"ref104\/cit104","unstructured":"AGA.  Guidance for the deletion of commercially confidential\nand personal information in an AusPAR. 2021."},{"key":"ref105\/cit105","unstructured":"EMA.  Draft guidance document on the identification\nof personal\ndata and commercially confidential information within the structure\nof the marketing authorisation application (MAA) dossier. 2024."},{"key":"ref106\/cit106","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.07.024"},{"key":"ref107\/cit107","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9938-6"},{"key":"ref108\/cit108","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.029"},{"key":"ref109\/cit109","doi-asserted-by":"publisher","DOI":"10.1016\/0271-5317(96)00036-X"},{"key":"ref110\/cit110","doi-asserted-by":"publisher","DOI":"10.1006\/rtph.1996.0109"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.4c01309","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.4c01309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T12:41:02Z","timestamp":1744029662000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.4c01309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,7]]}},"alternative-id":["10.1021\/acs.molpharmaceut.4c01309"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01309","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01309.s001","asserted-by":"subject"}]},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}